JAG1 and cancer: Therefore, JAG1 signaling and/or its active intracellular domain, JICD, can be considered an alternative therapeutic target for advanced PCs and detection marker of PCSC bulks from patients who experience therapeutic failure or have resistant and recurrent cancer.